Biotech Stock News (SRPT) (BMRN) (ACAD)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday April 25, 2016 Sarepta Therapeutics had an FDA advisory panel shoot down its drug Eteplirsen, used to treat patients with Duchenne Muscular Dystrophy — DMD. The panel voted against Eteplirsen on all questions. Even the last question which asked if Eteplirsen should be approved for DMD patients was also voted … Read more